CGIB September 2016 Newsletter

Articles and Interesting reading

Strategies for retaining clients
Healthcare Costly For Canadians
An average Canadian family of four (two parents with two children) will pay $11,494 for public healthcare insurance in 2016, says a study by the Fraser Institute. “Contrary to what many believe, healthcare in Canada isn’t free,” says Bacchus Barua, senior economist in the Fraser Institute’s Centre for Health Policy Studies and co-author of ‘The Price of Public Health Care Insurance.’ “While Canadians may not pay directly for medical services, they pay a substantial amount of money for healthcare through their taxes.” Most Canadians are unaware of the true cost of healthcare because they never see a bill for medical services and may only pay a small public health insurance ‘premium’ tax (in provinces that impose them). Moreover, general government revenue ? not a dedicated tax ? funds healthcare, making it difficult for Canadians to decipher how many of their tax dollars actually go towards public health insurance.
Retirees out of luck in battle over benefits
Ready to be recognized by your industry?

Looking to experience red-carpet treatment?

Want to be at a celebration you’ll never forget?

Make this YOUR year.

You’re committed to your clients, you’ve built and managed long term relationships, your customer service skills exceeded their expectations.

You deserve a NOMINATION!

Tell us about how you and your company accomplished big things this year and then get ready to celebrate with some of the most influential names in the business at our black tie awards gala.

5 things your business should do during the summer slowdown

Father living off $3.32 an hour launches class action against energy giant
Lawsuit alleges Just Energy misclassified employees as independent contractors to avoid legal obligations like minimum wage.

Average Canadian family pays more than $11,000 per year for health care – study–study-211717.aspx

Cystic fibrosis
In 2014, cystic fibrosis drug Kalydeco was making headlines for its efficacy and its $306,000 price tag. All provinces and territories have since included Kalydeco — at least in some circumstances — in their drug programs, according to Cystic Fibrosis Canada. Last year, private plan spending on cystic fibrosis medications increased 6.6 per cent and overall use increased by 6.4 per cent, Express Scripts’ 2015 drug trends report found. In January, Health Canada approved the drug Orkambi, which “would be available and suitable for almost half of the cystic fibrosis patient population,” says Po. “So it’s very good news from a clinical point of view because more patients can benefit from the new innovation,” she says, noting the $285,000 price tag.
Court of Appeal Upholds 26 Months Notice to Dependent Contractor
What Are the Consequences of Independent Contractor Misclassification?
Consultants seeking solutions amid disruption, competition
U.S. employers expect total health costs to jump 5% in 2016 and 2017
Ontario government’s “inflexible and intransigent” approach to bargaining violated Charter of Rights, judge rules
Ontario judge finds back-to-work legislation aimed at postal workers violates Charter
Governmental Factors Delay New Medicines
Several governmental factors are delaying the availability of new medicines in Canada’s public drug plans, says a Canadian Health Policy Institute study. This, in turn, has negative implications for access to innovative pharmaceuticals for the estimated 11.9 million Canadian patients who are eligible for publicly funded drug benefits. In addition, these delays and other quasi-governmental factors are shortening the effective period of market exclusivity for new drugs, which is significantly eroding the practical economic value of pharmaceutical patents in Canada. This potentially exposes Canada to trade disputes with its major trading partners. The study found that the actual period of market exclusivity for new drugs in the publicly insured markets in Canada is very short and varies significantly by jurisdiction. For drugs that experienced a generic entrant during the period of study, the actual effective life of a patent ranged from 3.4 to 6.5 years, and averaged six years. For drugs that had not yet experienced generic entry during the period of study, the expected effective life of a patent ranged from 7.4 to 11.6 years.

How to get out of a sales slump
Grow yourself, grow your business
There are clear benefits for business owners and senior advisers in being a mentor and a mentee
Are you Corporate clients doing regular benefits reviews? (They should be)
Millennials more likely to be taken in by fraud
The gift that keeps on selling

Seminars and Educational Events


October 04, 2016?International Centre, 6900 Airport Rd, Mississauga, ON

The 16th annual Pharmacy Solutions in Drug Plan Management Forum is a half-day conference designed to explore ways that current innovations in pharmacy can positively impact plan sponsors and their plan members.
This year’s theme, Better Health, Better Value, speaks to pharmacists’ virtually untapped role to support plan members taking medications to treat chronic diseases. Thanks to sweeping changes in healthcare legislation and examples set by publicly funded programs, pharmacists are equipped like never before to help ensure that plan members get the best possible health outcomes from their medicines, which means that plan sponsors get full value for their drug plan spend. As eligible medical practitioners, pharmacists are also growing their presence in the areas of point-of-care testing and healthcare coaching, to help prevent the incidence and impact of chronic disease.
New to the 2016 conference, this year’s event will feature exclusive Benefits Canada research that captures plan sponsor views about emerging pharmacy services. This will explore which services plan sponsors most want to see become part of health benefits plans. It will also capture current levels of understanding about key issues related to chronic disease management, such as adherence levels to medications.
To learn more about the role pharmacy services play in plans and their potential going forward, don’t miss the 2016 Pharmacy Solutions Forum.???PRICING
$129 + HST
Plan sponsors, benefit consultants, advisors, brokers, group insurance, PBM’s, TPA’s, pharmacies, pharmacists and other healthcare stakeholders.


Registration is now open for this year’s Arete Group Insurance Advisor Conference (AGIAC)

Join your fellow advisors at AGIAC 2016: Mythbusters – Fresh Thinking for Benefit Advisors.

Experts will blast away three common misconceptions affecting you and your clients:
• Myth #1: Employee mental health is not my clients’ business
• Myth #2: We’ve done all we can to manage drug plans
• Myth #3: Benefit reporting – it’s just a numbers game

This year’s event is a shorter day – from 10 a.m. until 2 p.m., which leaves you time to take care of business before and after.

Ticket prices have dropped, CE credits apply, venues are all easily accessible and have ample free parking.

Click here to visit the AGIAC page and register to attend in:
• Calgary, AB – November 1
• Burnaby, BC – November 3
• Vaughan, ON – November 8

Interested in booking a full table? Contact us at

Follow us on Twitter and Facebook to get up to the minute AGIAC updates.

Don’t miss this opportunity to get new insights into tough issues in a non-promotional, education-based environment. You’ll be glad you registered.

See you at the conference!


Leave a Reply

Your email address will not be published. Required fields are marked *